RMgmDB - Rodent Malaria genetically modified Parasites

Back to search results

Summary

RMgm-1465
Malaria parasiteP. berghei
Genotype
DisruptedGene model (rodent): PBANKA_1101300; Gene model (P.falciparum): PF3D7_0501300; Gene product: skeleton-binding protein 1 (SBP1)
Transgene
Transgene not Plasmodium: mCherry
Promoter: Gene model: PBANKA_0711900; Gene model (P.falciparum): PBANKA_0711900; Gene product: PBANKA_0711900 (HSP70)
3'UTR: Gene model: PBANKA_0711900; Gene product: heat shock protein 70 (HSP70)
Replacement locus: Gene model: PBANKA_0306000; Gene product: 6-cysteine protein (230p)
Transgene
Transgene not Plasmodium: Luciferase
Promoter: Gene model: PBANKA_1133300; Gene model (P.falciparum): PF3D7_1357100; Gene product: elongation factor 1-alpha (eef1a)
3'UTR: Gene model: PBANKA_0719300; Gene product: bifunctional dihydrofolate reductase-thymidylate synthase, putative (dhfr/ts)
Replacement locus: Gene model: PBANKA_0306000; Gene product: 6-cysteine protein (230p)
Phenotype Asexual bloodstage;
Last modified: 21 June 2016, 16:13
  *RMgm-1465
Successful modificationThe parasite was generated by the genetic modification
The mutant contains the following genetic modification(s) Gene disruption, Introduction of a transgene, Introduction of a transgene
Reference (PubMed-PMID number) Reference 1 (PMID number) : 27225796
MR4 number
Parent parasite used to introduce the genetic modification
Rodent Malaria ParasiteP. berghei
Parent strain/lineP. berghei ANKA
Name parent line/clone RMgm-1320
Other information parent lineThis transgenic reporter line expresses luciferase under the control of the eef1α (PBANKA_113330) promoter and, in addition, mCherry under the control of the hsp70 (PBANKA_071190) promoter. Both reporter cassettes are introduced into the silent 230p locus, using a single DNA construct. This transgenic line does not contain a drug-selectable marker
The mutant parasite was generated by
Name PI/ResearcherDe Niz M; Heussler V; Spielmann T
Name Group/DepartmentInstitute of Zoology
Name InstituteUniverstity of Hamburg
CityHamburg
CountryGermany
Name of the mutant parasite
RMgm numberRMgm-1465
Principal namePbΔsbp1
Alternative name
Standardized name
Is the mutant parasite cloned after genetic modificationYes
Phenotype
Asexual blood stageWhile no phenotypic differences were observed between the gene-deletion mutants and wild-type (wt) parasites during development in the mosquito or in the liver, blood stages of the mutants exhibited an attenuated phenotype in mice. While wt-infected C57B/6 mice died 7–9 days post infection as a result of complications typical for experimental cerebral malaria, PbΔsbp1-infected mice did not develop experimental cerebral malaria but died from hyperparasitemia 32–45 days post infection, respectively. A similar attenuation was also observed in infections in Balb/c mice. The parasitemia in the PbΔsbp1-infected mice was comparable to that of wt during the initial 2 days of infection, but was reduced compared with wt thereafter. Mutant parasites were predominantly found in reticulocytes throughout the course of infection, whereas virulent wt parasites were found in erythrocytes in the later course of infection.
In addition, mice infected with the PbΔsbp1 mutants showed a 3.6-fold increase in schizonts in the peripheral blood circulation compared to wt infections, respectively, indicating reduced sequestration of RBCs infected with mutant schizonts.
PbΔsbp1 parasites showed strongly reduced accumulation in the adipose tissue and lungs compared with wt, which is typical for a loss of CD36-mediated sequestration. Conversely, significantly increased accumulation of parasites was detected in the spleens of mice infected with PbΔsbp1 mutants. Higher accumulation in the spleen of non-sequestered schizonts has been attributed to increased removal of non-sequestering schizonts by the spleen.
Binding to mouse CD36 was significantly lower in PbΔsbp1 schizonts compared with wt schizonts with both plate-coated CD36 or CD36 expressed on CHO-745 cells.
Gametocyte/GameteNot tested
Fertilization and ookineteNot tested
OocystNot different from wild type
SporozoiteNot different from wild type
Liver stageNot different from wild type
Additional remarks phenotype

Mutant/mutation
The mutant lacks expression of SBP1 and expresses luciferase under the control of the eef1α promoter and mCherry under the control of the hsp70 promoter.

Protein (function)
SBP1 of P. falciparum is a Maurer's cleft protein and is part of the trafficking machinery that trafics PfEMP1 to the surface of infected red blood cells. SBP1 is a PEXEL-negative protein. Infected red blood cells with P. falciparum parasites lacking expression of SBP1 fail to cytoadhere to endothelial receptors of blood vessels, such as CD36 and ICAM1.

Phenotype
While no phenotypic differences were observed between the gene-deletion mutants and wild-type (wt) parasites during development in the mosquito or in the liver, blood stages of the mutants exhibited an attenuated phenotype in mice. While wt-infected C57B/6 mice died 7–9 days post infection as a result of complications typical for experimental cerebral malaria, PbΔsbp1-infected mice did not develop experimental cerebral malaria but died from hyperparasitemia 32–45 days post infection, respectively. A similar attenuation was also observed in infections in Balb/c mice. The parasitemia in the PbΔsbp1-infected mice was comparable to that of wt during the initial 2 days of infection, but was reduced compared with wt thereafter. Mutant parasites were predominantly found in reticulocytes throughout the course of infection, whereas virulent wt parasites were found in erythrocytes in the later course of infection.
In addition, mice infected with the PbΔsbp1 mutants showed a 3.6-fold increase in schizonts in the peripheral blood circulation compared to wt infections, respectively, indicating reduced sequestration of RBCs infected with mutant schizonts.
PbΔsbp1 parasites showed strongly reduced accumulation in the adipose tissue and lungs compared with wt, which is typical for a loss of CD36-mediated sequestration. Conversely, significantly increased accumulation of parasites was detected in the spleens of mice infected with PbΔsbp1 mutants. Higher accumulation in the spleen of non-sequestered schizonts has been attributed to increased removal of non-sequestering schizonts by the spleen.
Binding to mouse CD36 was significantly lower in PbΔsbp1 schizonts compared with wt schizonts with both plate-coated CD36 or CD36 expressed on CHO-745 cells.

Additional information
While the overall amino-acid similarity between the SBP1 of P. berghei and P. falciparum was rather low , the architecture of the protein features was similar and both proteins lack a PEXEL motif. In addition, three other findings indicated that these proteins are indeed orthologues. Firstly, the phylogenetic trees of these proteins are topologically concordant with the species tree of malaria parasites; secondly, a jackhmmer search arrived at the same proteins originally detected by our similarity searches; and finally, a re-examination of the genomic location revealed that the genes encoding SBP1 orthologues are in fact syntenic.

Immunofluorescence assays with immune sera showed that PbSBP1 was exported into P. berghei iRBCs where they were found in multiple discrete foci.

By introducing P. falciparum sbp1 gene into PbΔsbp1 evidence is presented that P. falciparum SBP1 complements the function of P. berghei SBP1: the growth-, sequestration- and virulence phenotype were (partly) restored in the complemented mutant)

Other mutants
RMgm-1452: An independent mutant lacking expression of SBP1


  Disrupted: Mutant parasite with a disrupted gene
Details of the target gene
Gene Model of Rodent Parasite PBANKA_1101300
Gene Model P. falciparum ortholog PF3D7_0501300
Gene productskeleton-binding protein 1
Gene product: Alternative nameSBP1
Details of the genetic modification
Inducable system usedNo
Additional remarks inducable system
Type of plasmid/construct used(Linear) plasmid double cross-over
PlasmoGEM (Sanger) construct/vector usedNo
Modified PlasmoGEM construct/vector usedNo
Plasmid/construct map
Plasmid/construct sequence
Restriction sites to linearize plasmid
Partial or complete disruption of the geneComplete
Additional remarks partial/complete disruption
Selectable marker used to select the mutant parasitetgdhfr
Promoter of the selectable markerpbdhfr
Selection (positive) procedurepyrimethamine
Selection (negative) procedureNo
Additional remarks genetic modification
Additional remarks selection procedure
Primer information: Primers used for amplification of the target sequences  Click to view information
Primer information: Primers used for amplification of the target sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Sequence Primer 3
Additional information primer 3
Sequence Primer 4
Additional information primer 4
Sequence Primer 5
Additional information primer 5
Sequence Primer 6
Additional information primer 6

  Transgene: Mutant parasite expressing a transgene
Type and details of transgene
Is the transgene Plasmodium derived Transgene: not Plasmodium
Transgene namemCherry
Details of the genetic modification
Inducable system usedNo
Additional remarks inducable system
Type of plasmid/construct(Linear) plasmid double cross-over
PlasmoGEM (Sanger) construct/vector usedNo
Modified PlasmoGEM construct/vector usedNo
Plasmid/construct map
Plasmid/construct sequence
Restriction sites to linearize plasmid
Selectable marker used to select the mutant parasitehdhfr
Promoter of the selectable markereef1a
Selection (positive) procedureNo
Selection (negative) procedure5-fluorocytosine (5-FC)
Additional remarks genetic modification
Additional remarks selection procedureThis reporter mutant expressing mCherry and Luciferase does not contain a drug-selectable marker.
The mutant has been generated in the reference line GIMOPbANKA (RMgm-687). The GIMO mother line is used for introduction of transgenes into the modified 230p locus through transfection with constructs that target the 230p locus. These constructs insert into the 230p locus (‘gene insertion’), thereby removing the hdhfr::yfcu selectable marker (‘marker out’) from the genome of the mother lines. Transgenic parasites that are marker-free are subsequently selected by applying negative drug selection using 5-FC. This selection procedure is performed in vivo in mice.
Other details transgene
Promoter
Gene Model of Parasite PBANKA_0711900
Gene Model P. falciparum ortholog PBANKA_0711900
Gene productPBANKA_0711900
Gene product: Alternative nameHSP70
Primer information details of the primers used for amplification of the promoter sequence  Click to view information
Primer information details of the primers used for amplification of the promoter sequence  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
3'-UTR
Gene Model of Parasite PBANKA_0711900
Gene productheat shock protein 70
Gene product: Alternative nameHSP70
Primer information details of the primers used for amplification the 3'-UTR sequences  Click to view information
Primer information details of the primers used for amplification the 3'-UTR sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Insertion/Replacement locus
Replacement / InsertionReplacement locus
Gene Model of Parasite PBANKA_0306000
Gene product6-cysteine protein
Gene product: Alternative name230p
Primer information details of the primers used for amplification of the target sequences  Click to view information
Primer information details of the primers used for amplification of the target sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Sequence Primer 3
Additional information primer 3
Sequence Primer 4
Additional information primer 4

  Transgene: Mutant parasite expressing a transgene
Type and details of transgene
Is the transgene Plasmodium derived Transgene: not Plasmodium
Transgene nameLuciferase
Details of the genetic modification
Inducable system usedNo
Additional remarks inducable system
Type of plasmid/construct(Linear) plasmid double cross-over
PlasmoGEM (Sanger) construct/vector usedNo
Modified PlasmoGEM construct/vector usedNo
Plasmid/construct map
Plasmid/construct sequence
Restriction sites to linearize plasmid
Selectable marker used to select the mutant parasitehdhfr
Promoter of the selectable markereef1a
Selection (positive) procedurepyrimethamine
Selection (negative) procedureNo
Additional remarks genetic modification
Additional remarks selection procedureThis reporter mutant expressing mCherry and Luciferase does not contain a drug-selectable marker.
The mutant has been generated in the reference line GIMOPbANKA (RMgm-687). The GIMO mother line is used for introduction of transgenes into the modified 230p locus through transfection with constructs that target the 230p locus. These constructs insert into the 230p locus (‘gene insertion’), thereby removing the hdhfr::yfcu selectable marker (‘marker out’) from the genome of the mother lines. Transgenic parasites that are marker-free are subsequently selected by applying negative drug selection using 5-FC. This selection procedure is performed in vivo in mice.
Other details transgene
Promoter
Gene Model of Parasite PBANKA_1133300
Gene Model P. falciparum ortholog PF3D7_1357100
Gene productelongation factor 1-alpha
Gene product: Alternative nameeef1a
Primer information details of the primers used for amplification of the promoter sequence  Click to view information
Primer information details of the primers used for amplification of the promoter sequence  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
3'-UTR
Gene Model of Parasite PBANKA_0719300
Gene productbifunctional dihydrofolate reductase-thymidylate synthase, putative
Gene product: Alternative namedhfr/ts
Primer information details of the primers used for amplification the 3'-UTR sequences  Click to view information
Primer information details of the primers used for amplification the 3'-UTR sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Insertion/Replacement locus
Replacement / InsertionReplacement locus
Gene Model of Parasite PBANKA_0306000
Gene product6-cysteine protein
Gene product: Alternative name230p
Primer information details of the primers used for amplification of the target sequences  Click to view information
Primer information details of the primers used for amplification of the target sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Sequence Primer 3
Additional information primer 3
Sequence Primer 4
Additional information primer 4